Anti-Human CD274 Recombinant Antibody (TAB-417CQ)

Customer Review

There are currently no Customer reviews or questions for TAB-417CQ. Click the button above to contact us or submit your feedback about this product.

Q&As

1. Is the anti-Durvalumab therapeutic antibody suitable for use in Western blotting?

   A: Yes, the anti-Durvalumab therapeutic antibody (TAB-417CQ) is suitable for use in Western blotting. It provides specific binding to Durvalumab, allowing for reliable detection in Western blot assays.

2. What are the storage recommendations for the anti-Durvalumab therapeutic antibody?

   A: The recommended storage condition for the anti-Durvalumab therapeutic antibody (TAB-417CQ) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-Durvalumab therapeutic antibody be used in immunoprecipitation assays?

   A: Yes, the anti-Durvalumab therapeutic antibody (TAB-417CQ) can be used in immunoprecipitation assays. It provides specific binding to Durvalumab, enabling the successful precipitation of the target protein from complex mixtures.

4. Is the anti-Durvalumab therapeutic antibody effective in ELISA applications?

   A: Yes, the anti-Durvalumab therapeutic antibody (TAB-417CQ) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of Durvalumab.

5. What is the optimal dilution for using the anti-Durvalumab therapeutic antibody in immunofluorescence?

   A: The optimal dilution for using the anti-Durvalumab therapeutic antibody (TAB-417CQ) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Li, Yumei, et al. "A novel multifunctional anti-PD-L1-CD16a-IL15 induces potent cancer cell killing in PD-L1-positive tumour cells." Translational Oncology 21 (2022): 101424. https://doi.org/10.1016/j.tranon.2022.101424
   This study explores the creation and efficacy of a novel multifunctional antibody, anti-PD-L1-CD16a-IL15, designed to target and kill PD-L1-overexpressing tumor cells. The researchers utilized recombinant human PD-L1-immunized llamas to develop anti-PD-L1 single-domain antibodies, which were then linked with anti-CD16a single-domain antibodies and the IL-15/IL-15Ra complex. This fusion protein, expressed and purified from HEK-293F cells, demonstrated significant in vitro and in vivo antitumor activity. It recruits T cells and activates NK cells to specifically target and kill PD-L1-positive tumor cells, showing enhanced efficacy over other antibody constructs in both cell cultures and xenograft models.
   Creative Biolabs played a crucial role in this research by supplying several key reagents. Specifically, they provided the durvalumab antibody (Cat#: TAB-417CQ) used for comparison in cell proliferation assays and cytotoxicity studies. The comprehensive testing of anti-PD-L1-CD16a-IL15, including binding affinity, immune cell recruitment, and tumor inhibition, was facilitated by these high-quality reagents from Creative Biolabs. The products contributed to the study's ability to demonstrate the potential of anti-PD-L1-CD16a-IL15 as a potent cancer immunotherapy.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-417CQ, RRID: AB_3111930)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Biosimilar Overview

Please refer to Durvalumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Durvalumab.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "Cd274"

Select a product category from the dropdown menu below to view related products.

Single Domain Antibodies Human Antibodies Mouse Antibodies Humanized Antibodies Chimeric Antibodies Neutralizing Antibodies Blocking Antibodies Rabbit Monoclonal Antibodies IgG Antibodies ScFv Antibodies Fab Antibodies ADCC Enhanced Antibodies Hexamer Antibodies NHP Antibodies FC Reagents & Kits ScFv-Fc Chimeras Extracellular Vesicle Antibodies IHC Kits & Antibodies Biparatopic Antibodies